Relmada Therapeutics, Inc. RLMD Return on equity

Return on equity at other companies

Johnson & JohnsonJNJ

25.7%-4.5pp

Merck & Co.MRK

7%-28.5pp

Aardvark Therapeutics, Inc.AARD

-58.8%—

CG OncologyCGON

-26.4%+9.3pp

Nuvectis Pharma, Inc.NVCT

-154.4%+79.4pp

ImmunomeIMNM

-64%-11.2pp

FAQ

What is Relmada Therapeutics, Inc.'s return on equity?

Relmada Therapeutics, Inc. (RLMD) reported return on equity of -48.8% in Q1 2026.

How has Relmada Therapeutics, Inc.'s return on equity changed year-over-year?

Relmada Therapeutics, Inc.'s return on equity increased by 69.5% year-over-year, from -160.3% to -48.8%.

What is the long-term trend for Relmada Therapeutics, Inc.'s return on equity?

Over 5 years (2020 to 2025), Relmada Therapeutics, Inc.'s return on equity has grown at a 11.8% compound annual growth rate (CAGR), from -53.7% to -94%.

What does return on equity mean?

Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.